Hero image

Pharmaceutical Products & Vaccines Supply Status

From time to time we may experience shortages of some products and may divest or discontinue others.

MSD UK customer services
0208 1548001
(9am-5pm, Mon-Fri)

(Out of normal working hours, during public holidays and weekends, please contact our UK switchboard on 0208 1548000).

Emergency patient supply order form

Please click here to download an emergency patient supply order form (for use by UK healthcare professionals only).


Product DescriptionSupply StatusEstimated Resupply Date
ZERBAXA® 1 g/0.5 g powder for
concentrate for solution for infusion
Out of Stock2022


Product DescriptionSupply StatusEstimated Resupply Date
GARDASIL® (National Immunisation Programme)N/APlease refer to ImmForm for NIP supply status
GARDASIL® 9Full Supply 
VAQTA® PaediatricFull Supply 
VAQTA® AdultFull Supply 
HBVAXPRO® 5mcgFull Supply 
HBVAXPRO® 10mcgFull Supply 
HBVAXPRO® 40mcgFull Supply 
M-M-RVAXPRO® (National Immunisation Programme)N/APlease refer to ImmForm for NIP supply status
M-M-RVAXPRO®Full Supply 
PNEUMOVAX® 23 (pre-filled syringes) National Immunisation ProgrammeN/APlease refer to ImmForm for NIP supply status
PNEUMOVAX® 23 (pre-filled syringes)Full Supply 
VARIVAX®Full Supply 
ZOSTAVAX® (National Immunisation Programme)N/APlease refer to ImmForm for NIP supply status
ZOSTAVAX®Full Supply


MSD appoint Alloga and Alliance Healthcare as its exclusive distribution partners

From 1st February 2022, Alloga will exclusively manage the warehousing and logistics (pre wholesaler) and Alliance Healthcare Limited will be the wholesaler for MSD products across the UK, ensuring MSD vaccines and medicines get to those who need them.

The new distribution partnership with Alliance Healthcare is the result of a competitive and thorough tender process which was conducted to enable MSD to continually meets the needs of patients and those who care for them by ensuring timely distribution of products to hospitals, pharmacies, GP surgeries and clinics. The new partnership includes a strong network of dispensing points across the UK – all of which will optimise support for patients and ensure that those who need MSD’s vaccines and products can receive them.

Class 2 Medicines Recall: Merck Sharp & Dohme Limited, Zerbaxa 1g/0.5g Powder for Concentrate for Solution for Infusion, EL (20)A/60

Information can be found here: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-merck-sharp-and-dohme-limited-zerbaxa-1g-slash-0-dot-5g-powder-for-concentrate-for-solution-for-infusion-el-20-a-slash-60

Zoely® 2.5 mg/1.5 mg film-coated tablets

As of 1st July 2020, Zoely® 2.5 mg/1.5 mg film-coated tablets are no longer supplied by MSD - refer to Theramex for more information.


We continue to track the COVID-19 outbreak closely and are focused on the safety of our employees and their families, continuity of supply and clinical trials, and supporting communities affected by this outbreak. Our thoughts are with the people of all affected areas.

Information about Esmeron® (rocuronium bromide) 10 mg/ml solution for injection

In relation to the COVID 19 crisis, we are experiencing a substantial increase in demand for our product Esmeron globally and the Company is actively engaged in increasing supply. To help the supply of rocuronium bromide to the UK market, a quantity of Esmeron which was packaged for Australia has been made available to the UK, as an interim measure.

The Medicines and Healthcare Regulatory Agency (MHRA) have approved the use of this supply for the UK.

The details of the batches that will be supplied are detailed below:

Batch numberExpiry date
T011923Feb 2023
T011924Feb 2023
T012129Feb 2023
T012763Feb 2023
T012764Feb 2023
T014251Feb 2023
T014929Mar 2023
T014958Mar 2023
U003785Nov 2023

A letter has been distributed to describe the differences in the packaging and that a PIL is not included in the pack, this letter can be found here.

Information about OncoTICE® (2-8 X 108 CFU Tice® BCG) powder for suspension

Due to increased global demand and as the primary supplier of OncoTICE®/(TICE® /BCG) in the UK, MSD has been experiencing supply constraints. To minimise disruption to patient care, available supply of OncoTICE®/(TICE® /BCG) is proportionally allocated across countries.

MSD are working with the Department of Health and Social Care (DHSC) and relevant professional organisations to ensure equitable distribution of the medicine across NHS.

 British Association of Urological Surgeons (BAUS) guidance may be found here: https://www.baus.org.uk/professionals/baus_business/news/209/restriction_of_bcg_supplies


Product Description
Rebetol 200 mg hard capsules

Back to products page

This page is intended for use by UK healthcare professionals only. Trademarks appearing on this website are owned, licensed to, promoted or distributed by Merck & Co., Inc., Kenilworth, NJ, USA, its subsidiaries or affiliates, except as noted.

Job code: GB-NON-05344 | Date of preparation: December 2021